Structural Heart Market Report 2025

The structural heart market size has grown strongly in recent years. It will grow from $14.9 billion in 2024 to $15.99 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to increased awareness and screening, supply chain resilience, increasing healthcare expenditure, market concentration, and increasing awareness of cardiovascular diseases.

The structural heart market size is expected to see strong growth in the next few years. It will grow to $22.43 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to the demand for heart valve devices, aging population, growing burden of cardiovascular diseases, market segmentation, regional market growth. Major trends in the forecast period include product launches, technological advancements, economic recovery, regulatory impositions, rising incidences of cardiovascular diseases, and innovative medical devices.

The anticipated rise in cardiovascular disorders is expected to drive the growth of the structural heart market in the future. Cardiovascular disorders encompass diseases affecting the heart and blood vessels, including conditions such as coronary artery disease, heart failure, and stroke. The increasing prevalence of cardiovascular disorders is primarily attributed to factors such as the aging population, shifts in lifestyle and diet, and escalating rates of obesity and diabetes. Structural heart devices and services play a crucial role in diagnosing and treating anomalies or disorders affecting the valves, chambers, and surrounding tissues of the heart, employing minimally invasive procedures instead of open-heart surgery to ensure efficient treatment with lower-risk complications. For example, a report published by the American College of Cardiology in August 2022 highlighted the projected increase in all four cardiovascular risk factors in the United States between 2025 and 2060, with diabetes expected to see a 39.3% rise to 55 million individuals, underscoring the significant role of cardiovascular disorders in propelling the structural heart market's growth.

The upward trend in obesity rates is anticipated to contribute to the expansion of the structural heart market. Obesity, characterized by excessive body fat accumulation resulting in a body mass index (BMI) of 30 or higher, is a medical condition associated with heightened cardiovascular challenges. The persistent global obesity epidemic drives the demand for advanced structural heart interventions to address the increased cardiovascular risks linked to obesity. As indicated by a report from the World Obesity Federation in May 2022, it is projected that by 2030, one billion people globally, including 1 in 5 women and 1 in 7 men, will be living with obesity, and this number is expected to increase to 4 billion people or 51% of the global population by 2035. Thus, the escalating rates of obesity are instrumental in steering the growth of the structural heart market.

Technological advancements have emerged as a prominent trend gaining traction in the structural heart market. Leading market players are channeling their efforts into creating innovative products to strengthen their market position. For instance, in February 2023, Eko Health, a US-based digital health company, introduced the SENSORA cardiac disease detection platform, utilizing artificial intelligence for non-invasive heart disease detection in primary care. SENSORA features digital stethoscopes to capture and analyze heart sounds and electrical signals, aiding in key decision-making by identifying structural murmurs, a sign of valvular heart disease. This technology enhances operational efficiency by reducing delays in care delivery, length of stay, and readmission rates, contributing to both patient and physician satisfaction.

Key players in the structural heart market are innovating advanced products, including transcatheter edge-to-edge repair (TEER) systems, to improve minimally invasive treatment options for heart valve diseases. TEER systems are minimally invasive medical devices designed to address heart valve conditions, particularly mitral valve regurgitation. For example, in April 2024, Abbott Laboratories, a US-based medical device firm, gained approval from the Food and Drug Administration (FDA), a US federal agency responsible for safeguarding public health, for its device called TriClip. TriClip is an innovative TEER system that is delivered through a vein in the leg, allowing for valve repair without the need for open-heart surgery, making it suitable for patients who might be at greater risk due to age or pre-existing health conditions. The device operates by using clips to grasp and bring together the leaflets of the tricuspid valve, thereby decreasing regurgitation and enhancing blood flow.

In February 2022, Genesis MedTech, a Singapore-based medical technology company, acquired JC Medical (JCM), a US-based company operating in the structural heart market, for an undisclosed amount. This acquisition enables Genesis MedTech to enhance its product portfolio with J-Valve, a minimally invasive transcatheter aortic valve replacement (TAVR) device, reinforcing its position in the market by offering comprehensive solutions for structural heart disease.

Major companies operating in the structural heart market include Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Edwards Lifesciences Corporation, Trane Technologies, Lepu Medical Technology Co. Ltd., LivaNova PLC, Biomerics LLC, Venus Medtech (Hangzhou) Inc., Cryolife Inc., Endologix Inc., Shockwave Medica Inc., Braile Biomédica, JenaValve Technology Inc., Corvia Medical Inc, HLT Medical, On-X Life Technologies Inc., Symetis SA, Magenta Therapeutics, PASCAL Medical, Micro Interventional Devices Inc., CardioKinetix Inc, Tendyne Holdings Inc., Q'Apel Medical Inc., Neovasc Inc., NVT AG, Z-Medical GmbH + Co. KG.

North America was the largest region in the structural heart market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the structural heart market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the structural heart market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Structural heart is a subspecialty within cardiology that concentrates on diagnosing and treating structural abnormalities or diseases of the heart, particularly those impacting the valves, chambers, and surrounding structures. This field typically involves minimally invasive procedures conducted in a catheterization laboratory as opposed to traditional open-heart surgery.

The primary categories of structural heart products encompass occluders, annuloplasty rings, heart valve balloons, and other related devices. Occluder systems are specifically designed to provide a conduit for delivering devices into the heart's chambers, coronary arteries, and peripheral vasculature. These devices are utilized in patients with specific types of atrial septal defects featuring right atrial or ventricle enlargement, preventing paradoxical embolism. The diverse procedures employing structural heart products include heart valve stenosis, heart valve regurgitation, and left atrial appendage closure. These procedures cater to various end-users such as hospitals, ambulatory surgical centers, and cardiac centers.

The structural heart market research report is one of a series of new reports that provides structural heart market statistics, including structural heart industry global market size, regional shares, competitors with a structural heart market share, detailed structural heart market segments, market trends and opportunities, and any further data you may need to thrive in the structural heart industry. This structural heart market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The structural heart market consists of revenues earned by entities by providing services such as patient evaluation, diagnosis, treatment planning, surgical or interventional procedures, and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The structural heart market also includes sales of transcatheter heart valves, closure devices, and implantable devices that are used during procedures. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.